Overall verdict
Sell
1.4/10
1-year performance
-93.93%
Score breakdown
Down 93.9% over 1 year, 0% of the 52-week range.
Strongest: Financial strength 7.2/10. Weakest: Shareholder return 0.0/10.
PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company's PB-718 a long-acting GLP-1 receptor agonist, that have completed b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH) ;
and PB-1902 an Opioid receptor antagonist, which is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the first-line treatment of type 2 diabetes mellitus and obesity; and PB-722 that has completed the FDA orphan drug qualification certification for use in the treatment of congenital hyperinsulinemia. Additionally, the company is conducting preclinical studies test on PB-2301, a GLP-1/glucose-dependent insulinotropic polypeptide; and PB-2309, a GLP-1/GIP/ glucagon triple receptor agonist for the treatment of type 2 diabetes mellitus, NASH, and obesity.
It has research and development collaboration with rani therapeutics to expand obesity pipeline across multiple novel candidates. PegBio Co., Ltd. was incorporated in 2008 and is based in Hangzhou, China.
Sector
Health Care
Industry
Biotechnology
Primary listing
Hkex
China
CEO
Min Xu
Founded
2008
Employees
58
Revenue / employee
0 HKD
Next earnings
November 25, 2026 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
77.00 HKD
52-week low
3.40 HKD
1-year performance
-93.93%
Declining
Year-to-date performance
-95.08%
Declining
Drawdown
-95.58%
Major drawdown
Position in the 52-week range
0% of range
ROIC -123.5%, ROE -126.5%.
Net margin
—
Sector -223.82%|S&P 13.15%
Gross margin
—
Return on equity (ROE)
-126.55%
Negative
Sector -58.62%|S&P 16.61%
Return on invested capital (ROIC)
-123.45%
Negative
Free cash flow margin (FCF)
—
Revenue (trailing 12 months)
0 HKD
Revenue growth (1y)
—
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.4x|S&P 24.1x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 14.4x|S&P 15.2x
PEG
—
Sector -0.03|S&P 0.90
Market cap
1.8Md HKD
Financial strength
7.2/10Cash covers 267.8% of the debt, net debt/EBITDA 0.8x.
Net debt / EBITDA
0.8x
Solid
Gearing (net debt / equity)
-95.97%
Net cash
Cash
469M HKD
Cash / market cap
25.82%
Very solid
Cash / total debt
267.78%
Net cash
Interest coverage
-98.9x
Stretched
Net debt
-294M HKD
Equity
306M HKD
Closed daily candles, 17 months
Last close on October 21, 2026: 3.69 HKD
- MM204.79
- MM505.42
- MM20028.36
- RSI 1422.0
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-18.18%
200-day average slope, 3 months
-37.21%
50-day average slope, 1 month
-9.63%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
3.51 % per day
Volatility change
-54.19%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.44 | — | — | — | — |
| 2027 | -0.19 | — | — | — | — |
Amounts in millions of HKD, EPS in HKD per share. In brackets, the number of analysts. Consensus as of November 26, 2025.
Same sub-industry: 781 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AGEN | 5.6 | 4.9 | 289M USD | 2.4x | 69.3 % | 34.4 % | -11.7 % | 6.7x | -34.1 % | 44.8 % | ||
| 2 | SRZN | 5.5 | 4.3 | 298M USD | Not meaningful (loss) | -3042.9 % | 408.6 % | — | 2.2x | -11.8 % | 87.6 % | ||
| 3 | 6915 | 4.9 | 4.9 | 285M USD | — | — | 6.7 % | — | -0.7x | — | -7.8 % | ||
| 4 | PRLD | 4.7 | 3.5 | 291M USD | Not meaningful (loss) | -269.7 % | 73.4 % | -50.5 % | 2.0x | -11.4 % | 182.9 % | ||
| 5 | BNTC | 4.4 | N/A | 297M USD | Not meaningful (loss) | — | — | -33.1 % | 3.5x | -5.9 % | -46.2 % | ||
| 6 | NWBO | 3.5 | 4.0 | 281M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.7 % | -25.0 % | ||
| 7 | IPSC | 3.4 | 1.5 | 292M USD | Not meaningful (loss) | -100.6 % | 1556.8 % | -41.9 % | 0.9x | -30.2 % | 182.2 % | ||
| 8 | XFOR | 3.2 | 3.0 | 298M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -4.4 % | ||
| 9 | 2565 | 1.4 | 1.4 | 231M USD | Not meaningful (loss) | — | — | -123.5 % | 0.8x | -14.7 % | -93.9 % |
